Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | RGS12 | O14924 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599095 | 0.85 | RGS12 (0.78) | MAPK14HTTHDAC1HDAC6RGS12 | |
| SCHEMBL12918551 | 0.82 | MAPK14 (0.77) | MAPK14HTTHDAC1HDAC6FAAH | |
| SCHEMBL8301611 | 0.80 | MAPK14 (1.00) | MAPK14HTTHDAC1HDAC6KMT2A | |
| SCHEMBL8439563 | 0.78 | MAPK14 (0.82) | MAPK14HTTHDAC1HDAC6KMT2A | |
| SCHEMBL8445048 | 0.78 | MAPK14 (0.82) | MAPK14HTTHDAC1HDAC6KMT2A | |
| SCHEMBL8303336 | 0.76 | MAPK14 (0.82) | MAPK14HTTHDAC1HDAC6KMT2A | |
| SCHEMBL17954125 | 0.74 | GRIN2B (0.60) | FAAHKMT2AALDH1A1MAPTNR1H4 | |
| SCHEMBL3601029 | 0.74 | FAAH (1.00) | FAAHMAPT | |
| SCHEMBL29335990 | 0.73 | MAPK14 (0.73) | MAPK14HTTHDAC1HDAC6KMT2A | |
| SCHEMBL27381217 | 0.73 | GABRA1 (0.55) | MAPK14HTTKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | MAPK14 2278/4885HTT 3033/4885HDAC1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.